BMY | Bristol-Myers Squibb Company

Healthcare | Drug Manufacturers - General | USA | NYSE

Index	S&P 500	P/E	18.88	EPS (ttm)	3.43	Insider Own	0.07%	Shs Outstand	2.10B	Perf Week	-1.31%
Market Cap	134.10B	Forward P/E	7.96	EPS next Y	8.14	Insider Trans	-17.03%	Shs Float	2.10B	Perf Month	-5.39%
Income	7.31B	PEG	5.03	EPS next Q	2.02	Inst Own	79.40%	Short Float / Ratio	1.02% / 2.65	Perf Quarter	-1.38%
Sales	45.85B	P/S	2.92	EPS this Y	-5.40%	Inst Trans	-0.72%	Short Interest	21.49M	Perf Half Y	-18.93%
Book/sh	15.16	P/B	4.27	EPS next Y	1.22%	ROA	7.50%	Target Price	79.70	Perf Year	-14.94%
Cash/sh	4.48	P/C	14.47	EPS next 5Y	3.75%	ROE	22.80%	52W Range	63.07 - 81.43	Perf YTD	-9.94%
Dividend	2.28	P/FCF	20.84	EPS past 5Y	4.50%	ROI	11.80%	52W High	-20.43%	Beta	0.43
Dividend %	3.52%	Quick Ratio	1.30	Sales past 5Y	17.30%	Gross Margin	77.80%	52W Low	2.74%	ATR	1.10
Employees	34300	Current Ratio	1.40	Sales Q/Q	-2.70%	Oper. Margin	22.70%	RSI (14)	40.60	Volatility	1.23% 1.64%
Optionable	Yes	Debt/Eq	1.19	EPS Q/Q	81.30%	Profit Margin	15.90%	Rel Volume	0.87	Prev Close	65.31
Shortable	Yes	LT Debt/Eq	1.10	Earnings	Apr 27 BMO	Payout	63.40%	Avg Volume	8.10M	Price	64.80
Recom	2.40	SMA20	-1.60%	SMA50	-4.44%	SMA200	-9.22%	Volume	7,067,647	Change	-0.78%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-06-23	Initiated	Jefferies	Hold	$62
Jan-17-23	Initiated	Cantor Fitzgerald	Overweight	$95
Nov-18-22	Initiated	Credit Suisse	Neutral	$78
Oct-10-22	Downgrade	Guggenheim	Buy → Neutral
Sep-14-22	Downgrade	Berenberg	Buy → Hold	$82 → $76
Jun-03-22	Downgrade	Raymond James	Outperform → Mkt Perform
Apr-06-22	Resumed	Morgan Stanley	Underweight	$64
Dec-17-21	Initiated	Goldman	Buy	$72
Dec-09-21	Resumed	Wells Fargo	Equal Weight	$58
Nov-19-21	Initiated	BMO Capital Markets	Outperform	$72
Nov-01-21	Downgrade	Argus	Buy → Hold
Jul-27-21	Resumed	Truist	Buy	$74
Apr-30-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$70 → $62
Apr-13-21	Upgrade	Truist	Hold → Buy
Nov-16-20	Upgrade	Societe Generale	Hold → Buy	$76
Nov-10-20	Resumed	Bernstein	Mkt Perform
Nov-06-20	Downgrade	Gabelli & Co	Buy → Hold
Oct-19-20	Upgrade	Guggenheim	Neutral → Buy	$70
Sep-29-20	Initiated	Berenberg	Buy	$73
Jul-28-20	Initiated	Raymond James	Outperform	$75

Show Previous Ratings

Jun-08-23 04:16PM	Bristol Myers Squibb Receives U.S. FDA Approval of New State-of-the-Art Cell Therapy Manufacturing Facility in Devens, Massachusetts (Business Wire)
06:59AM	Bristol Myers Squibb to Report Results for Second Quarter 2023 on July 27, 2023 (Business Wire)
Jun-07-23 05:45PM	Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know (Zacks)
07:00AM	Here's Why Bristol-Myers Squibb (NYSE:BMY) Has Caught The Eye Of Investors (Simply Wall St.)
Jun-05-23 12:46PM	Analyst Report: Bristol-Myers Squibb Company (Morningstar Research)
10:22AM	Loading…
10:22AM	Bristol Myers (BMY) Announces Upbeat Data From NSCLC Study (Zacks)
Jun-04-23 08:00AM	Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer (Business Wire)
Jun-03-23 06:14AM	3 Dividend Stocks You Can Buy Without Any Hesitation (Motley Fool)
Jun-02-23 03:55PM	10 Stocks Jim Cramer and Hedge Funds Have In Common (Insider Monkey)
01:17PM	The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree (Investor's Business Daily)
07:00AM	Bristol-Myers Squibb Company (NYSE:BMY) is largely controlled by institutional shareholders who own 78% of the company (Simply Wall St.)
04:59AM	The Zacks Analyst Blog Highlights NVIDIA, Bristol-Myers Squibb, ICICI Bank, Palo Alto and Walgreens Boots Alliance (Zacks)
Jun-01-23 05:45PM	Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know (Zacks)
04:52PM	Top Analyst Reports for NVIDIA, Bristol-Myers Squibb & ICICI Bank (Zacks)
12:46PM	Bristol Myers (BMY) Loses 10.5% Year-to-Date: What Lies Ahead? (Zacks)
11:35AM	Loading…
11:35AM	Biotech Stock Roundup: MRTX Falls on Study Failure, LXRX Drug Wins Approval & More (Zacks)
10:04AM	15 Best Healthcare Stocks To Buy Now (Insider Monkey)
09:00AM	3 Top Stocks That Just Went on Sale (Motley Fool)
06:59AM	Bristol Myers Squibb to Participate in Upcoming Investor Conferences (Business Wire)
May-31-23 12:09PM	Bristol Myers' (BMY) Lung Cancer Drug NDA Gets Priority Review (Zacks)
11:15AM	Is Bristol Myers Squibb a Top Dividend Stock? (Motley Fool)
06:59AM	Bristol Myers Squibb to Hold R&D Day on September 14 (Business Wire)
May-30-23 12:50PM	Bristol-Myers Squibb Breaks a Key Support Area: What's Next? (TheStreet.com)
09:24AM	Bristol Myers Squibb to Present Late-Breaking Data for Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma at 2023 International Conference on Malignant Lymphoma (Business Wire)
06:59AM	U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibbs Application for Repotrectinib for the Treatment of Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (Business Wire)
May-29-23 10:08AM	FDA Accepts Iovance's (IOVA) BLA Filing for Melanoma Drug (Zacks)
08:00AM	We Think Bristol-Myers Squibb (NYSE:BMY) Can Stay On Top Of Its Debt (Simply Wall St.)
May-26-23 12:32PM	Bristol Myers (BMY) Thrombosis Drug Gets Fast Track Designation (Zacks)
09:56AM	Bristol Myers' CAR T Cell Therapy Shows Deep, Durable Efficacy In Blood Cancer Patients (Benzinga)
08:10AM	Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expre... (Business Wire)
05:05PM	Loading…
May-25-23 05:05PM	Bristol Myers Squibbs Breyanzi (lisocabtagene maraleucel) is First and Only CAR T to Deliver Deep and Durable Efficacy in Pivotal Multicenter Trial in Relapsed or Refractory Chronic Lymphocytic Leukemia, Based on Data Presented at ASCO 2023 (Business Wire)
05:00PM	Bristol Myers Squibb to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl® (luspatercept-aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) (Business Wire)
02:25PM	Mirati's (MRTX) Sitravatinib Fails Lung Cancer Study, Stock Down 8% (Zacks)
06:59AM	Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation (Business Wire)
04:03AM	14 Best Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
May-24-23 09:33AM	14 Best Healthcare Dividend Stocks to Buy (Insider Monkey)
May-23-23 12:30PM	Bristol Myers (BMY) Reports Pulmonary Fibrosis Study Results (Zacks)
May-22-23 11:01AM	Bristol Myers Squibbs Investigational LPA1 Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis (Business Wire)
May-20-23 07:00AM	Bristol-Myers Squibb (NYSE:BMY) sheds 3.3% this week, as yearly returns fall more in line with earnings growth (Simply Wall St.)
May-19-23 10:07AM	1 Dirt Cheap Dividend Stock to Buy in May (Motley Fool)
May-17-23 12:38PM	Pfizer, Amgen, and 7 More Cheap Healthcare Stocks for Investors to Consider (Barrons.com)
May-15-23 08:00AM	A Closer Look At Bristol-Myers Squibb Company's (NYSE:BMY) Impressive ROE (Simply Wall St.)
May-11-23 09:17AM	Is Bristol-Myers Squibb Stock a Buy Now? (Motley Fool)
09:00AM	3 High-Yielding Dividend Stocks That Could Pay You Forever (Motley Fool)
May-10-23 10:00AM	Bristol-Myers Squibb Insiders Sell US$38m Of Stock, Possibly Signalling Caution \ (Simply Wall St.)
08:45AM	3 Things About Bristol-Myers Squibb That Smart Investors Know (Motley Fool)
May-09-23 04:09PM	15 Biggest Immunotherapy Companies in the World (Insider Monkey)
11:15AM	Pharma ETFs Gain Post Q1 Earnings (Zacks)
May-05-23 12:27PM	Prothena (PRTA) Q1 Earnings and Revenues Miss Estimates (Zacks)
10:15AM	Which Is the Better Passive Income Stock, Eli Lilly or Bristol Myers Squibb? (Motley Fool)
10:00AM	Should Income Investors Buy This Blue Chip Dividend Stock? (Motley Fool)
07:00AM	Here's Why We Think Bristol-Myers Squibb (NYSE:BMY) Is Well Worth Watching (Simply Wall St.)
06:58AM	Daily Vickers Top Buyers & Sellers for 05/05/2023 (Argus Research)
May-03-23 08:20AM	Want Passive Income at a Fair Price? Consider Buying This Dividend Growth Stock (Motley Fool)
06:59AM	Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy (Business Wire)
May-02-23 11:38AM	Patients Lose Access to Free Medicines Amid Spat Between Drugmakers, Health Plans (The Wall Street Journal)
11:21AM	Why Immatics Stock Is Soaring Today (Motley Fool)
09:01AM	15 Best Income Stocks to Buy According to Analysts (Insider Monkey)
06:59AM	Bristol Myers Squibb to Participate in Bank of America Securities 2023 Healthcare Conference (Business Wire)
May-01-23 07:05AM	U.S. FDA Accepts for Priority Review Supplemental Biologics License Application and EMA Validates Application for Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) (Business Wire)
06:59AM	Bristol Myers Squibbs TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma Meet Primary Endpoint of Overall Response Rate (Business Wire)
Apr-30-23 10:00AM	In the wake of Bristol-Myers Squibb Company's (NYSE:BMY) latest US$8.0b market cap drop, institutional owners may be forced to take severe actions (Simply Wall St.)
Apr-29-23 09:53PM	27 Largest Biotech Companies in the US (Insider Monkey)
Apr-28-23 12:26AM	Q1 2023 Bristol-Myers Squibb Co Earnings Call (Thomson Reuters StreetEvents)
Apr-27-23 01:45PM	Bristol Myers Squibb Posts Lower Q1 Sales As Revlimid Generic Erosion Bites, Chairman & CEO Giovanni Caforio To Step Down (Benzinga)
12:16PM	Bristol-Myers (BMY) Q1 Earnings Beat, Revlimid Generics Hurt Sales (Zacks)
10:40AM	Analyst Report: Bristol-Myers Squibb Company (Morningstar Research)
10:00AM	Compared to Estimates, Bristol Myers (BMY) Q1 Earnings: A Look at Key Metrics (Zacks)
09:10AM	UPDATE 1-Bristol Myers looks to new CEO as competition from generic drugs heats up (Reuters)
08:15AM	Bristol Myers Squibb (BMY) Surpasses Q1 Earnings Estimates (Zacks)
07:07AM	Bristol Myers looks to new CEO as competition from generic drugs heats up (Reuters)
06:59AM	Bristol Myers Squibb Reports First Quarter Financial Results for 2023 (Business Wire)
06:59AM	Bristol Myers posts lower Q1 sales as Revlimid falls (Reuters)
Apr-26-23 06:41PM	UPDATE 2-Bristol Myers CEO Caforio to step down (Reuters)
05:14PM	CORRECTED-UPDATE 1-Bristol Myers CEO Caforio steps down (Reuters)
04:59PM	Bristol Myers CEO Caforio to step down (Reuters)
04:35PM	Bristol-Myers CEO Giovanni Caforio to Step Down (The Wall Street Journal)
04:14PM	Bristol Myers Squibb Announces Leadership Transition Plan (Business Wire)
02:42PM	Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM) (Business Wire)
09:28AM	Drug/Biotech Stocks' Q1 Earnings Due Apr 27: LLY, ABBV & More (Zacks)
08:46AM	Should You Buy Bristol Myers Squibb (BMY) Ahead of Earnings? (Zacks)
06:59AM	Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production (Business Wire)
05:56AM	The Zacks Analyst Blog Highlights Bristol-Myers Squibb, Medtronic, Altria Group, Target and FedEx (Zacks)
02:37AM	14 Best Income Stocks To Invest In (Insider Monkey)
Apr-25-23 01:47PM	Q1 Earnings Scorecard and Fresh Analyst Reports for Bristol-Myers, Medtronic & Altria Group (Zacks)
09:40AM	Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock (Zacks)
Apr-24-23 11:57AM	Bristol-Myers (BMY) to Report Q1 Earnings: What+'s in Store? (Zacks)
10:00AM	Earnings Preview: Vertex Pharmaceuticals (VRTX) Q1 Earnings Expected to Decline (Zacks)
07:00AM	We Think Bristol-Myers Squibb (NYSE:BMY) Can Stay On Top Of Its Debt (Simply Wall St.)
Apr-21-23 12:16PM	12 Best Pharma Dividend Stocks To Buy in 2023 (Insider Monkey)
Apr-20-23 10:02AM	Bristol Myers Squibb (BMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
08:13AM	Amgen (AMGN) Wins Patent Appeal for Blockbuster Psoriasis Drug (Zacks)
Apr-19-23 05:50PM	Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know (Zacks)
09:00AM	Bristol-Myers Squibb (NYSE:BMY) shareholders have earned a 9.7% CAGR over the last five years (Simply Wall St.)
Apr-18-23 07:09AM	Analyst Report: Bristol-Myers Squibb Co. (Argus Research)
06:54AM	Market Digest: BMY, MTB (Argus Research)
Apr-17-23 01:13PM	Bristol Myers (BMY), TSVT Application for Abecma Accepted (Zacks)
06:59AM	Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma (Business Wire)
Apr-15-23 07:01AM	How Did Bristol-Myers Squibb Company's (NYSE:BMY) 20% ROE Fare Against The Industry? (Simply Wall St.)
Apr-13-23 03:30PM	Drug CEO: How the industry is fighting to sway impact of Texas abortion pill ruling (Yahoo Finance)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lenkowsky Adam	EVP, Chief Commercial Officer	Jun 03	Option Exercise	0.00	1,077	0	1,077	Jun 06 07:39 PM
VESSEY RUPERT	EVP & President, Research	May 03	Sale	67.06	50,385	3,378,818	47,751	May 04 05:51 PM
Greenlees Sharon	SVP & Controller	May 02	Option Exercise	0.00	1,017	0	728	May 03 07:36 PM
Mily Elizabeth	EVP, Strategy & BD	Apr 01	Option Exercise	0.00	6,346	0	35,873	Apr 04 08:40 PM
Shanahan Karin	EVP, Glob. Prod. Dev. & Supply	Apr 01	Option Exercise	0.00	3,306	0	4,918	Apr 04 08:40 PM
Mily Elizabeth	EVP, Strategy & BD	Mar 10	Option Exercise	0.00	29,636	0	38,173	Mar 14 08:40 PM
VESSEY RUPERT	EVP & President, Research	Mar 10	Option Exercise	0.00	66,935	0	118,263	Mar 14 08:34 PM
LEUNG SANDRA	EVP, General Counsel	Mar 10	Option Exercise	0.00	57,990	0	356,920	Mar 14 08:28 PM
Powell Ann	EVP, Chief Human Resources	Mar 10	Option Exercise	0.00	34,447	0	53,100	Mar 14 08:18 PM
Hirawat Samit	EVP,Chief Med.Offr.,Drug Dev.	Mar 10	Option Exercise	0.00	38,978	0	54,035	Mar 14 08:18 PM
Weese Michelle	EVP, Corporate Affairs	Mar 10	Option Exercise	0.00	1,590	0	2,793	Mar 14 08:14 PM
Shanahan Karin	EVP, Glob. Prod. Dev. & Supply	Mar 10	Option Exercise	0.00	2,447	0	2,447	Mar 14 08:12 PM
Caforio Giovanni	Board Chair and CEO	Mar 10	Option Exercise	0.00	234,676	0	431,381	Mar 14 08:13 PM
Elkins David V	EVP, Chief Financial Officer	Mar 10	Option Exercise	0.00	71,871	0	185,308	Mar 14 08:13 PM
BOERNER CHRISTOPHER S.	EVP, Chief Commercial Officer	Mar 10	Option Exercise	0.00	59,111	0	91,880	Mar 14 08:13 PM
Meyers Gregory Scott	EVP, Chief Digital & Tech Off.	Mar 10	Option Exercise	0.00	2,836	0	4,648	Mar 14 08:14 PM
Caforio Giovanni	Board Chair and CEO	Feb 06	Sale	74.65	240,000	17,916,000	236,104	Feb 08 08:09 PM
Powell Ann	EVP, Chief Human Resources	Feb 06	Sale	74.69	11,183	835,258	23,043	Feb 08 08:09 PM
Meyers Gregory Scott	EVP, Chief Digital & Tech Off.	Feb 01	Option Exercise	0.00	2,543	0	2,543	Feb 03 07:18 PM
BOERNER CHRISTOPHER S.	EVP, Chief Commercial Officer	Dec 02	Option Exercise	0.00	2,637	0	44,603	Dec 06 07:32 PM
Elkins David V	EVP, Chief Financial Officer	Dec 02	Option Exercise	0.00	8,792	0	128,578	Dec 06 06:44 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Dec 02	Option Exercise	0.00	8,792	0	65,871	Dec 06 06:43 PM
Powell Ann	EVP, Chief Human Resources	Nov 09	Sale	80.45	16,250	1,307,312	34,226	Nov 14 06:57 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Nov 07	Option Exercise	58.31	52,604	3,067,529	102,989	Nov 09 08:38 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Nov 07	Sale	78.88	45,910	3,621,381	57,079	Nov 09 08:38 PM
Caforio Giovanni	Board Chair and CEO	Sep 20	Sale	69.71	25,000	1,742,750	476,104	Sep 22 05:12 PM
Caforio Giovanni	Board Chair and CEO	Sep 15	Sale	71.84	50,000	3,592,000	501,104	Sep 16 05:12 PM
Powell Ann	EVP, Chief Human Resources	Sep 14	Sale	70.75	25,000	1,768,750	50,476	Sep 15 07:29 PM
Elkins David V	EVP, Chief Financial Officer	Sep 13	Option Exercise	48.49	123,277	5,977,702	223,737	Sep 15 07:29 PM
Elkins David V	EVP, Chief Financial Officer	Sep 13	Sale	71.30	133,951	9,551,167	100,460	Sep 15 07:29 PM
Weese Michelle	EVP, Corporate Affairs	Jul 01	Option Exercise	0.00	1,885	0	1,885	Jul 05 04:29 PM
Hirawat Samit	EVP,Chief Med.Offr.,Drug Dev.	Jul 01	Option Exercise	0.00	9,356	0	26,078	Jul 05 04:28 PM
Caforio Giovanni	Board Chair and CEO	Jun 13	Sale	74.04	30,000	2,221,200	551,104	Jun 14 05:58 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BMY | Bristol-Myers Squibb Company

Upgrade your FINVIZ experience